The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...
The checkpoint inhibitor is now approved, based on CheckMate 77T findings, for neoadjuvant/adjuvant use in patients with ...
Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...
The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.
The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...
Medpage Today on MSN2d
De-Intensified Therapy Misses Mark in HPV-Positive Oropharyngeal CancerTwo strategies to de-escalate treatment for human papillomavirus (HPV)-positive oropharyngeal cancer failed to show ...
During a Case-Based Roundtable® event, Laahn Foster, MD, discussed the 2024 update to the RELATIVITY-047 trial in advanced ...
In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) cleared Opdivo (nivolumab) for use with platinum-based chemo to reduce the size ...
Researchers compared health-related quality of life with nivolumab added to first-line chemo vs chemo alone in patients with ...
Nivolumab, given with or without ipilimumab, showed durable 10-year survival outcomes in patients with advanced melanoma.
No benefit seen for rechallenge with nivolumab after progression in the post-immune checkpoint inhibitor setting.
The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback